The goal of this newsletter is to give an overview of what is happening around multiple myeloma in terms of medical developments. This is achieved by monitoring news articles, PR releases and scientific reports on one hand. Conversations from HCPs, digital opinion leaders and other influencers attending congresses, offering their opinion on treatments and commenting on new developments on the other hand.
Objectives
Who will benefit from this newsletter?
Any professionals interested in keeping up with developments around multiple myeloma:
- Marketers
- Business Analysts
- But also HCPs who want to anticipate the future landscape of MM management
Scope
The scope of the analysis is focused on mentions coming worldwide.*
There were a total of 30K mentions from patients recorded during the listening period from June 1st, 2023, to June 30th, 2023.
A majority of mentions came from News (46%), Twitter (42%), Tumblr (7%), Forums (2%), Reddit (1%), Blogs (1%) and Instagram (1%).
A total of 8K unique authors were identified.
*: Myeloma OR multiplemyeloma OR #Mmsm OR #Myeloma* OR #Curemyeloma* OR #Mmmrd OR #mmsm OR title: ("multiple myeloma" OR myeloma)
Methodology
Discussions around #ASCO23 took centre stage this month with the CAR-T cilta-cel emerging as the top drug in term of mention amongst HCPs.
Share of voice: Topics of conversations
Share of voice: Molecules
#ASCO23 Focus on Multiple Myeloma
This year’s edition was heavily focused on CAR-T cell therapies and bispecific antibodies.
Highly anticipated results from the CARTITUDE-4 reflect this. Other development of note include teclistamab and talquetamab and corresponding trials RedirecTT-1 and MajesTEC-1.
Topics of discussions (type of treatment)
Most mentioned clinical trials
Most mentioned molecules
#EHA23 Focus on Multiple Myeloma
Overall bispecific antibodies elranatamab and talquetamab took center stage online during #eha23 with the results of MagnetisMM-3 being particularly cited.
Influenced by the results from CARTITUTE-4 + additional results from CARTITUDE-1, CAR-T therapies were also of high interest with cilta-cel the most mentioned molecule.
Topics of discussions (type of treatment)
Most mentioned clinical trials
Most mentioned molecules
Back from EHA 2023 – AplusA and Dr. BLIN presented MM poster during the congress
Dr. Nicolas BLIN, hematologist at Nantes University Hospital, accompanied our experts and had the opportunity to present the poster:
ACTUAL USAGE OF CURRENT SYSTEMIC TREATMENTS AND INFLUENCE OF KEY DRIVERS FOR MULTIPLE MYELOMA IN THE FIRST 2 LINES OF THERAPY. DATA FROM REAL-WORLD STUDY IN EU5 COUNTRIES
that he co-created with our AplusA experts Melissa YILMAZ and Siegfried ERTL.
You can download and access the poster by clicking the button below:
During the Friday evening poster session, Dr. BLIN presented the results in a detailed video presentation. Access the video by clicking the button below and learn more about our MM data from real-world study:
.png?width=417&height=273&name=APLUSA%20at%20EHA2023%20(2).png)
After the congress, we've held a live webinar with Dr. Nicolas BLIN who highlighted the key moments of the EHA.
Co-moderated by our experts Melissa YILMAZ and Siegfried ERTL, Dr. BLIN presented the latest news on hematology, commented some abstracts based on ongoing clinical trials and shared his thoughts on different hot topics in hematology (Multiple Myeloma, Acute Myeloid Leukemia, Myelofibrosis, bispecific antibodies, CAR T cell therapies, etc.)
Fill this short form to discover the entire newsletter
and to receive next SMML newsletters directly in your mailbox!
👇 👇